Anúncio
Anúncio

ADPT

ADPT logo

Adaptive Biotechnologies Corporation Common Stock

15.92
USD
Patrocinado
-0.32
-1.98%
02 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

15.71

-0.21
-1.31%

Relatórios de Lucros ADPT

Rácio de surpresa positiva

ADPT separação 21 de 26 últimas estimativas.

81%

Próximo Relatório

Data do Próximo Relatório
09 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$60.48M
/
-$0.18
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-35.64%
/
-400.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+27.43%
/
-21.74%

Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue

On 05 de nov. de 2025, ADPT reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.14 USD, resulting in a 140.21% surprise. Revenue reached 93.97 milhão, compared to an expected 65.94 milhão, with a 42.52% difference. The market reacted with a -11.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.18 USD, with revenue projected to reach 60.48 milhão USD, implying an diminuir of -400.00% EPS, and diminuir of -35.64% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
logo
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
logo
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
For Q3 2025, Adaptive Biotechnologies Corporation Common Stock reported EPS of $0.06, beating estimates by 140.21%, and revenue of $93.97M, 42.52% above expectations.
The stock price moved down -11.54%, changed from $17.59 before the earnings release to $15.56 the day after.
The next earning report is scheduled for 09 de fev. de 2026.
Based on 10 analistas, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.18 and revenue of $60.48M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio